Dr. Errin L. Manney, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 146
Licensed in Illinois since 2018, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
IL license 036-146972 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Advocate Christ Hospital & Medical Center Oak Lawn, IL
- Advocate Trinity Hospital Chicago, IL
Medical groups
- Advocate Health and Hospitals Corporation (3,118 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 146
- Services billed
- 842
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 247 | 122 |
| Insertion of needle into vein for collection of blood sample | 147 | 100 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 75 | 75 |
| Hemoglobin a1c level | 54 | 32 |
| Established patient office or other outpatient visit, 20-29 minutes | 53 | 44 |
| Administration of influenza virus vaccine | 37 | 37 |
| Influenza vaccine split virus, preservative free | 35 | 35 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 19 | 16 |
| Urine microalbumin (protein) level | 18 | 18 |
| Administration of pneumococcal vaccine | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 59 payments worth $1,139 in total to this clinician.
| Pfizer Inc. | $161 |
|---|---|
| Novo Nordisk Inc | $156 |
| Amgen Inc. | $115 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $97.66 |
| Dexcom, Inc. | $75.11 |
| AbbVie Inc. | $69.55 |
| Lilly USA, LLC | $65.23 |
| Ardelyx, Inc. | $59.94 |
| Food and Beverage | $1,139 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $95,921 in research payments for these studies, mostly to the institutions running them.
- Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
AstraZeneca Pharmaceuticals LP - UC P3: Double-Blind Treat Straight Through
F. Hoffmann-la Roche AG - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - UC P3: Double-Blind Treat Straight Through
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.